Friday, October 9, 2026

HomeHealth NewsFDA approves Datroway for HR-positive, HER2-negative breast cancer

FDA approves Datroway for HR-positive, HER2-negative breast cancer

- Advertisement -

The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.

…

Click here to view the original article.

- Advertisment -
- Advertisement -

Recently Viewed